PulseJournal ClubResearchersJournalsExplore
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 1, 2024JACC Heart FailureOpen Access

Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does mavacamten treatment improve LVOT gradients, NT-proBNP levels, and NYHA functional class in patients with symptomatic obstructive hypertrophic cardiomyopathy?

Population

Patients with symptomatic obstructive hypertrophic cardiomyopathy

Comparison

Mavacamten treatment

Follow-up

Median 62-week

Authors

FRFlorian RaderAOArtur OręziakLCLubna Choudhury

Discussion

Loading...

Member takes

Overview

May support extended use in symptomatic obstructive HCM; leaves open need for randomized confirmation.

Key Points

  • To evaluate the efficacy of mavacamten in treating symptomatic obstructive hypertrophic cardiomyopathy.
  • Patients received mavacamten for 62 weeks.
  • Follow-up was conducted over a median duration of 62 weeks.
  • Clinical improvements were measured using LVOT gradients and NT-proBNP levels.
  • Mavacamten treatment led to significant reductions in LVOT gradients and NT-proBNP levels.
  • Patients experienced improved NYHA functional class scores over the treatment period.
  • Treatment was well tolerated among participants during the follow-up.

Structured PICO

Does mavacamten treatment improve LVOT gradients, NT-proBNP levels, and NYHA functional class in patients with symptomatic obstructive hypertrophic cardiomyopathy?

P
Population
Patients with symptomatic obstructive hypertrophic cardiomyopathy
I
Intervention
Mavacamten
O
Outcome
LVOT gradients, NT-proBNP levels, and NYHA functional class

Mavacamten provides durable improvements in hemodynamics, biomarkers, and functional class over a median 62-week follow-up in symptomatic obstructive hypertrophic cardiomyopathy.

Cite This Study

Rader et al. (2024) studied this question.

synapsesocial.com/papers/69cdb9b28a370bf2b7387b7ehttps://doi.org/10.1016/j.jchf.2023.09.028
View Full Paper
Ask AI
Bookmark
Share